Peptidförening enligt USP 795 och 797: Dokumentation

Vilket USP-kapitel styr din peptid?

Peptidsyntes Omfattningsbeslutet beror på om det färdiga preparatet måste vara sterilt vid administreringsstället – inte på om utgångsmaterialet är en peptid, ett biologiskt ämne, eller en liten molekyl.

USP General Chapter <795> för icke-steril blandning gäller när preparatet inte krävs att vara sterilt vid administrering: de flesta orala vätskor, torrt pulver fyller, aktuella lösningar, och lyofiliserade forskningsmaterial som uteslutande används för in vitro-arbete. USP General Chapter <797> för steril blandning gäller när preparatet måste vara fritt från livsdugliga mikroorganismer och uppfylla endotoxingränserna vid administreringsstället - injicerbara, oftalmik, intratekala preparat, och varje väg där kontaminering skapar en direkt risk för patient- eller djursäkerhet.

Den praktiska innebörden för upphandling är att väg och form måste finnas i inköpsordern – inte härledd från sekvensen. En leverantör som inte frågar om avsedd användning innan offert kan inte ta fram ett kapitelspecifikt dokumentationspaket, eftersom kraven skiljer sig avsevärt mellan raderna i tabellen ovan. Att dokumentera det samtalet skriftligt skyddar båda parter när partiet granskas nedströms.

Identitetsdokumentation: Vad "Bekräftad" faktiskt betyder för anpassade sekvenser

Under USP sammansättningslogik, identitetsbekräftelse är kategoriskt skild från renhetsbedömning. Identitet svarar på en kategorisk fråga - är detta den rätta molekylen? — medan renhet svarar på en kvantitativ — hur mycket av den korrekta molekylen är närvarande? Att endast citera HPLC-data som identitetsbevis är ett dokumentationsfel som inspektörer som är utbildade i att sammansätta standarder kommer att flagga rutinmässigt.

Masspektrometri som primärt identitetsbevis

För anpassade och modifierade peptider, ESI-MS eller MALDI-TOF är den accepterade primära metoden för identitetsbekräftelse. Acceptanskriteriet för standardiserade anpassade sekvenser på enhetsupplösningsinstrument är ett observerat [M+H]⁺ eller multiplicera [M+nH]ⁿ⁺ jon inom ±0,5 Da från den teoretiska monoisotopiska massan. För högupplösta ESI-MS-data, kriteriet skärps till ��2 ppm.

CoA ska rapportera tre punkter, inte en: den teoretiska massan, den observerade massan, och det uppmätta deltat. Ett "godkänt" uttalande utan stödjande numerisk kontext är inte reproducerbar och inte verifierbar av det mottagande laboratoriets QC-team.

För isotopmärkta eller deuteriumberikade peptider som används som interna standarder, ytterligare två datapunkter krävs: isotophöljets form måste motsvara den teoretiska isotopologfördelningen för den deklarerade anrikningsnivån, och Δ-massan i förhållande till den omärkta analogen måste falla inom det förväntade fönstret. Ett anrikningspåstående som inte stöds av envelopanalys kan inte bekräftas enbart med molekylvikt.

För PEGylerad, häftade, eller makrocykliska peptider där molekylvikten överstiger tillförlitligt MALDI-TOF-intervall eller där laddningshöljena är diffusa, LC-MS with spectral deconvolution or MS/MS fragment ion confirmation should be specified in the analytical method reference on the CoA. If the supplier’s standard platform cannot accommodate the molecular complexity, that is information the buyer needs before synthesis begins — not after the CoA has been issued.

Kromatografisk identitetsbekräftelse

RP-HPLC functions as an orthogonal, corroborating method — not the primary one. Retention time reproducibility across lots, measured under identical column, mobil fas, and gradient conditions, confirms that the material has the expected hydrophobicity and retention profile. This is particularly useful for detecting epimerization, where a D-residue substitution may produce a compound with the correct molecular weight but shifted retention behavior.

The CoA must specify: retention time of the main peak, column stationary phase and dimensions, partikelstorlek, mobile phase composition (both aqueous and organic components), gradient program, flödeshastighet, column temperature if controlled, och detektionsvåglängd. A retention time without method context cannot be reproduced and therefore provides no confirmatory value.

The counterion form introduces a systematic effect that is rarely disclosed without asking. Peptides released from Fmoc SPPS with residual TFA counterion absorb at 214 nm and can produce inflated purity percentages by area normalization relative to the same peptide as the acetate salt. If a lot will be used in cell-based assays — where residual TFA is cytotoxic — the CoA should explicitly confirm counterion exchange and specify the final salt form. This detail belongs in the MFR and the CoA, not in a post-receipt email thread.

Renhetsstandarder och CoA-krav för modifierade peptider

Definiera acceptanskriterierna innan syntesen börjar

The most avoidable source of lot rejection in custom peptide procurement is a purity specification that was not agreed upon before synthesis commenced. For standard research-grade batches, ≥95% purity by RP-HPLC area normalization is a widely applied acceptance threshold. For material destined for sterile compounding or IND-enabling use, ≥98% purity by HPLC is the industry-typical expectation, though the applicable specification should be documented in the quality agreement rather than assumed. These are industry-typical practice benchmarks, not chapter-mandated numeric limits — which makes their explicit documentation in a purchase-order specification all the more important.

A complete pre-synthesis purity specification for a complex modified peptide should define: (1) minimum main-peak purity by RP-HPLC, (2) maximum acceptable levels for the most probable degradation products — desaminidation, oxidized species at Met or Trp, Asp-Pro bond hydrolysis products, deletion sequences — (3) the endotoxin limit in EU/mg if the compound will be formulated for sterile use, och (4) motjonsform. Writing these down before ordering converts a buyer-preference into a binding quality agreement. Establishing them after delivery converts a buyer’s disappointment into a supplier’s negotiating position.

Vad en kompatibel CoA måste innehålla

A CoA that does not include the following fields cannot serve as a complete qualification record under USP compounding documentation logic:

A CoA missing any field in this table is incomplete for compounding-level documentation purposes. The appropriate action is to request the missing data before accepting the lot — not to annotate the gap in the receiving record and proceed.

⚠️ Varning: Accepting an incomplete CoA and documenting the gap in your IMA record does not close the gap for audit purposes. It creates a traceable acknowledgment that the incoming material standard was knowingly not met.

Förvaringsvillkor, Beyond-Use Dating, och stabilitetsdata bakom dem

Beyond-use dating is one of the most frequently misunderstood concepts at the supplier-buyer interface. BUD is not expiration dating. Expiration dating is assigned by the original manufacturer under ICH Q1A-compliant stability studies and reflects validated shelf life. BUD is calculated from the date or time of compounding and reflects how long the preparation is expected to retain its composition under specified storage conditions, as established conservatively by the compounder (ASHP, The Pharmacist Guide to Assigning a Beyond-Use Date).

The governing rule for BUD assignment: the BUD must be the earlier of the sterility-based default limit and any shorter limit imposed by a component expiry, ingredient retest date, or documented stability finding. Storage conditions do not extend a BUD beyond ingredient limits — they determine which default BUD category applies when no limiting component constraint exists.

For non-sterile preparations under <795>, the defaults in the absence of supporting stability data are: aqueous solutions, 14 days at controlled cold temperature; non-aqueous liquids and solid formulations, 6 månader. For lyophilized peptide powders handled as non-sterile raw materials, a 6-month frozen BUD is defensible only if the container is sealed, desiccated, in inert atmosphere, and held continuously at −20°C or below. Freeze-thaw cycling resets the risk exposure and should trigger documented reassessment.

For sterile preparations under <797>, extended BUD (beyond the 12-hour room-temperature or 24-hour refrigerated defaults for Category 1 CSPs) requires documented stability data from the actual formulation in the actual container-closure system under the actual storage conditions (USP General Chapter <797> FAQ, 2023). A supplier who quotes a 30-day BUD on a sterile peptide solution without a stability study reference is assigning a number, not a scientifically supported date.

Peptide-specific vulnerabilities relevant to storage and BUD decisions include: oxidation at Met, Cys, and Trp residues under aerobic conditions; Asp-Pro hydrolysis under acidic conditions and at temperatures above controlled room temperature; aggregation in hydrophobic or disulfide-containing sequences on freeze-thaw cycling; and racemization at certain residues under prolonged refrigeration. These vulnerabilities must be stated in the supplier’s technical dossier — not assumed by the buyer — because they directly affect what storage conditions are appropriate and how conservatively the BUD should be set.

Märkningskrav som håller upp under revision

The minimum label content for a compounded sterile preparation is specified in USP General Chapter <797>: names and amounts or concentrations of all active ingredients, the BUD (as date, or hour and date where the 4-hour administration window applies), storage conditions, the compounder’s identity, and a clear indication that the preparation is compounded. When the preparation is distributed rather than directly administered, the label must also specify the time period within which administration must begin.

For custom research peptides, the label should additionally carry the sequence identifier or abbreviated modification code. This is particularly important for variant libraries, isotopically labeled analogs, or PEGylation-degree variants where visual inspection provides no basis for discrimination. A label that says “Peptide A, 5 mg/mL” when four structurally related peptides are in storage is not audit-ready for a regulated research environment.

For dry peptide powders released as non-sterile raw materials under <795>, the label content required for your incoming material acceptance SOP is the practical standard: partinummer, sekvens, mass or mole quantity, purity result (or CoA reference number), motjonsform, storage temperature and conditions, and a retest or BUD date. A QR code linking to the digital CoA is a best practice — it reduces transcription error and accelerates IMA review — though it is not a chapter requirement.

De fem analytiska uppgifterna som varje leverantör av sterila sammansättningar bör tillhandahålla

For sterile-grade peptide materials, five record categories create the defensible evidence chain from raw ingredient to released lot. Each serves a distinct quality-system function. Kollektivt, they answer the question an auditor must ask: was this lot made correctly, by qualified people, in a controlled environment, and released based on complete data?

1. Master Formula Record (MFR). The MFR is the standing procedure: every ingredient by name and grade, kvantiteter, equipment identification, step-by-step synthesis and processing procedure, in-process acceptance criteria, and quality-control checkpoints. För anpassade peptider, the MFR is synthesis-specific — it references resin loading, coupling cycle parameters, klyvningsförhållanden, and purification method. It is the reference baseline against which any deviation is evaluated. A deviation without an MFR has no context.

2. Compounding Record (CR) / Batch Record. The CR documents what actually happened for a specific lot: operator identity and date, actual quantities and instruments used, equipment identification, environmental conditions at time of preparation, deviations from the MFR and their disposition, and both operator and second-person verification. The CR is distinct from the MFR — it is lot-specific, not procedure-specific. A lot with only an MFR and no CR has no execution record.

3. Personnel Training and Competency Records. USP <797> requires documented competency for all personnel involved in sterile compounding, including gloved fingertip and thumb sampling, media-fill qualification, surface sampling, garbing and cleaning competency, and annual or periodic requalification (ASHP Guidelines on Compounding Sterile Preparations, 2014). Training completion certificates are necessary but not sufficient — documented competency assessment results are required.

4. Environmental Monitoring Log. A classified cleanroom designation is a one-time certification; an environmental monitoring log is the ongoing evidence that conditions inside that classification are being maintained. The log must include viable air sampling and surface sampling results, non-viable particle counts, pressure differential readings, temperature and humidity data, action limits for each monitoring location, and documented corrective actions for every exceedance. A log that shows results without action limits cannot be evaluated; a log that shows only non-viable particle data without viable monitoring is incomplete for <797> compliance. The vendor-level supplier governance framework for raw materials and sterilization provides one model for how environmental monitoring connects to lot release decisions.

5. Analytiska releaseposter. These are the source data behind the CoA: the full HPLC chromatogram with integration table, the complete MS spectrum with deconvolution where applicable, the LAL endotoxin assay report including the method standard curve, and the sterility test report where the lot was compounded under sterile conditions. Release records must be retained in retrievable form for a minimum period defined by the applicable quality standard — typically at least 3 years for research-grade material. A qualified supplier should be able to produce these records upon request without requiring a formal audit declaration.

Vanliga dokumentationsluckor som misslyckas med inspektioner

The deficiencies that appear most predictably in peptide supplier documentation reviews are not complex or unusual. They are standard gaps that process-driven quality systems close routinely — and that documentation-light suppliers never close without external pressure. Om

BUD assigned without stability data. A 30-day or 90-day BUD on a sterile formulation that references no stability study is an unsupported number. Inspectors ask for the supporting data as a first-line query; “standard industry practice” is not an acceptable reference, and “same compound used elsewhere” is not stability data for your formulation.

CoA missing method reference or column specification. A reported HPLC purity of 98.5% cannot be independently verified without the method. Column stationary phase, dimensions, partikelstorlek, mobil fas, lutning, flödeshastighet, temperatur, and wavelength must all appear on the CoA or in a method reference document cited by the CoA. If the column has changed between lots, that fact must be documented.

Endotoxin limit not stated. For sterile materials, the CoA must state the acceptance limit (till exempel, <1 EU/mg or <0.5 EU/mg, depending on the application), the LAL method variant, and the actual result. A result reported without a stated limit leaves the QA team unable to evaluate whether the lot passed the relevant criterion — which is a failing condition in an audit, regardless of the numerical value.

No corrective action documentation for environmental exceedances. An environmental monitoring log that shows an action-limit exceedance with no subsequent corrective action entry indicates either that no investigation was conducted or that it was not documented. Both are problematic. Investigators treat this as a systemic quality failure rather than a record-keeping lapse.

Identity confirmed by chromatography alone. HPLC retention time can corroborate identity but cannot confirm it for custom sequences. Scrambled sequences, racemized residues, and deletion analogs can co-elute under standard RP-HPLC conditions at the expected retention time. MS data is the only method that provides unambiguous molecular identity confirmation for custom sequences; its absence from the CoA is an identity documentation gap, not a purity issue.

Anpassa leverantörsdokumentation med ditt interna QMS

The documentation requirements above are useful only if they map cleanly to your internal quality management system. The most common failure mode is not the absence of supplier records — it is the format mismatch. CoAs with non-standard field labels, batch records in proprietary formats, or analytical reports citing internal method codes without an external translation create friction at incoming material acceptance and extend review timelines for every lot.

The solution is a quality agreement negotiated before the first purchase order, not in response to the first lot rejection. A quality agreement for peptide materials should specify: the exact fields required on the CoA, the format and naming conventions for batch records, the timeframe for providing raw analytical data on request, the process for communicating post-delivery deviations, and record retention obligations. Once in place, it converts your QMS requirements into binding supplier deliverables rather than post-receipt negotiation points.

Three elements are non-negotiable in any quality agreement, regardless of material grade or order volume: a lot-specific CoA with full method references (not a template with a lot number inserted), raw instrument data available on request within a defined window, and a written deviation disclosure process with notification timelines. Establishing these before synthesis begins eliminates most of the downstream quality disputes that consume project time.

For research teams building or reviewing a supplier qualification program, the practical approach to building peptide vendor continuity before a study begins with the quality agreement structure, not with the first CoA review. The incoming material acceptance SOP cannot function as a quality filter if it is only applied after materials have already been produced to an unaligned standard.

For modified or complex custom sequences — PEGylated peptides, cyclic scaffolds, isotope-labeled internal standards — the analytical method selection for identity and purity confirmation requires discussion before synthesis, not after lot release. De MOL Ändrar anpassad plattform för peptidsyntes provides lot-specific CoAs as a standard deliverable, with HPLC chromatograms, MS-spektra, and endotoxin LAL reports available on request through the quality documentation process for sterile-grade material. Research teams that need to confirm the full documentation package before committing to a lot can request a lot-specific data review prior to order placement.

If your incoming peptide documentation requirements are not yet fully defined, or if you are managing the transition from a previous supplier with a different documentation standard, the first practical step is a pre-order technical conversation. Contact the MOL Changes synthesis and QC team to align on CoA field requirements, analytical method specifications, and batch record format before synthesis is initiated — it is significantly faster to establish that alignment in writing before a lot exists than to renegotiate it after.